# Salient Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/salient-bio

- Industry: Healthcare
- Headquarters: London, UK
- Website: www.salient.bio
- Total disclosed funding: $3.2M
- Latest round: Seed (Sep 3, 2025)
- Investors on record: 2

## About

Salient Bio, based in the UK, provides advanced laboratory services specializing in microbiome testing and pathology services, offering efficient solutions for healthcare providers.Founded in 2020, Salient Bio focuses on microbiome analysis and pathology services. The company has changed its business strategy to concentrate on diagnostic tests aimed at healthcare providers. The headquarters is located in London, UK. Recently, Salient Bio raised GBP 2.35 million in Seed funding, led by Thena Capital with participation from Vanneck Ltd. This funding marks their first deal to date, with the total amount raised being GBP 2.35 million.Salient Bio specializes in advanced laboratory services with a focus on microbiome testing and pathology services. The company's core offerings include a flexible range of blood- and stool-based pathology services delivered with a 24-hour turnaround time, which enables healthcare providers to obtain critical health insights efficiently. Salient Bio also provides customized sampling kits tailored to the specific needs of healthcare professionals, ensuring optimal data collection for clinical trials or individual patient testing. Their services are aimed at healthcare providers, including laboratories, private general practitioners, and pharmacies, primarily within the United Kingdom and Europe. By utilizing state-of-the-art automated technology, the firm ensures reliable and accurate analysis of samples, offering bespoke reports that cater to the specific requirements of their clients and end-users.Salient Bio's revenue model is grounded in providing specialized laboratory services to healthcare providers through direct B2B transactions. The company facilitates transactions by offering various service packages that are tailored to the needs of their clients, ensuring that they can easily access the necessary testing and analysis tools. Clients engage with Salient Bio on a contractual basis, likely involving service agreements that may include consistent orders of sampling kits and recurring pathology services. This structured approach allows healthcare providers to maintain a steady flow of essential laboratory services, thereby enhancing their operational capabilities and patient care offerings without needing to manage their own testing infrastructure.In September 2025, Salient Bio raised GBP 2.35 million in Seed funding led by Thena Capital, with participation from Vanneck Ltd. The company will utilize this funding to support the market introduction of its diagnostic test for Inflammatory Bowel Disease, which is based on microbiome analysis. Salient Bio is also looking to expand its services into new geographic regions across Europe, aiming to establish a broader presence in the healthcare market by the end of 2026.

## Funding rounds

- Seed, Sep 3, 2025, $3.2M — Vanneck Ltd, THENA Capital

## Investors

- Vanneck Ltd — Seed
- THENA Capital (https://capitalatlas.ai/funds/thena-capital) — Seed